Parkinson's sufferers in the UK offered new treatment but who will pay the costs?
This article was originally published in Clinica
Executive Summary
An electronic implant for treating patients with Parkinson's disease was launched in the UK last week. The Activa device uses tiny electric shocks to block brain signals that cause the disease's characteristic symptoms including tremors, rigidity and unstable posture. It can also treat the disabling side effects of widely-used drug treatments.
You may also be interested in...
ImmunityBio Will Aim Anktiva At Large Share Of Bladder Cancer Market
Execs Richard Adcock and Patrick Soon-Shiong told Scrip the company sees an addressable US population of about 20,000 and is aiming for ease of physician adoption.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.